A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With Achondroplasia
This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in children with ACH who have completed two years of treatment in the 111-202 study.
Indication: Achondroplasia
Modality: small molecule
Target: BMN 111
Sponsor: BioMarin Pharmaceutical
Source URL: ClinicalTrials.gov
Source updated: Mar 13, 2026
Ingested: Jun 20, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: BMN 111
View original source fields
Condition raw: Achondroplasia
Condition normalized: Achondroplasia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: BMN 111
Target normalized: BMN 111